4 vaccines caused deaths and injuries:

  • Covid-19 mrna vaccine moderna (cx-024414)
  • Covid-19 mrna vaccine pfizer- biontech
  • Covid-19 vaccine astrazeneca (chadox1 ncov-19)
  • Covid-19 vaccine janssen (ad26.cov2.S)

There are 683,688 serious injuries which equals over 50%  recorded from the total of injuries.

EudraVigilance is the system for managing and analyzing information on suspected adverse reactions to medicines that have been authorized or being studied in clinical trials in the European Economic Area (EEA). The European Medicines Agency (EMA) operates the system on behalf of the European Union (EU) medicines regulatory network.

EudraVigilance supports safe and effective use of medicines by facilitating:

  • Electronic exchange of individual case safety reports (ICSRs) between EMA, national competent authorities (NCAs), marketing authorisation holders (MAHs) and sponsors of clinical trials in the EEA.
  • Early detection and evaluation of possible safety signals; better product information for medicines authorised in the EEA.

The EudraVigilance system includes:

  • A fully automated safety and message-processing mechanism using XML-based messaging.
  • A large pharmacovigilance database with query and tracking functions

The Management Board of the European Medicines Agency first approved the EudraVigilance Access Policy in December 2010.

Below are data summarizing injury and death responses for each of the four COVID-19 shots  through June 5, 2021.

The fatalities are organized by symptoms, and some deaths may have been caused by a combination of symptoms.

Total reactions for the experimental mRNA vaccine Tozinameran (code BNT162b2,Comirnaty) from BioNTech/ Pfizer: 6,732 deaths and 502,162 injuries.

  • 14,819   Blood and lymphatic system disorders incl. 74 deaths
  • 11,018   Cardiac disorders incl. 843 deaths
  • 90       Congenital, familial and genetic disorders incl. 5 deaths
  • 6,146 Ear and labyrinth disorders incl. 3 deaths
  • 216    Endocrine disorders
  • 7,119 Eye disorders incl. 17 deaths
  • 45,616   Gastrointestinal disorders incl. 332 deaths
  • 140,516 General disorders and administration site conditions incl. 2,079 deaths
  • 387    Hepatobiliary disorders incl. 28  deaths
  • 5,436 Immune system disorders incl. 32 deaths
  • 15,632   Infections and infestations incl. 711 deaths
  • 5,552 Injury, poisoning and procedural complications incl. 94   deaths
  • 11,782   Investigations incl. 260   deaths
  • 3,730 Metabolism and nutrition disorders incl. 129 deaths
  • 71,816   Musculoskeletal and connective tissue disorders incl. 84 deaths
  • 295    Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl. 21 deaths
  • 90,427   Nervous system disorders incl. 692 deaths
  • 330    Pregnancy, puerperium and perinatal conditions incl. 11 deaths
  • 100    Product issues
  • 8,902 Psychiatric disorders incl. 99 deaths
  • 1,547 Renal and urinary disorders incl. 103 deaths
  • 2,052 Reproductive system and breast disorders incl. 3 deaths
  • 21,055   Respiratory, thoracic and mediastinal disorders incl. 777 deaths
  • 23,678   Skin and subcutaneous tissue disorders incl. 60  deaths
  • 750    Social circumstances incl. 9 deaths
  • 222    Surgical and medical procedures incl. 15 deaths
  • 12,929   Vascular disorders incl. 251 deaths

Total reactions for the experimental mRNA vaccine mRNA-1273(CX-024414) from Moderna: 3,821 deaths and 101,767 injuries 

  • 1,826 Blood and lymphatic system disorders incl. 27 deaths
  • 2,822 Cardiac disorders incl. 409 deaths
  • 31       Congenital, familial and genetic disorders incl. 2 deaths
  • 1,171 Ear and labyrinth disorders
  • 64       Endocrine disorders incl. 1 death
  • 1,575 Eye disorders incl. 5 deaths
  • 8,770 Gastrointestinal disorders incl. 124 deaths
  • 28,047   General disorders and administration site conditions incl. 1,646 deaths
  • 180    Hepatobiliary disorders incl. 10  deaths
  • 936    Immune system disorders incl. 5 deaths
  • 3,333 Infections and infestations incl. 219 deaths
  • 2,013 Injury, poisoning and procedural complications incl. 71   deaths
  • 2,292 Investigations incl. 85 deaths
  • 1,137 Metabolism and nutrition disorders incl. 77 deaths
  • 12,483   Musculoskeletal and connective tissue disorders incl. 69 deaths
  • 113    Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl. 14 deaths
  • 17,861   Nervous system disorders incl. 382 deaths
  • 171    Pregnancy, puerperium and perinatal conditions incl. 1 death
  • 18       Product issues
  • 2,071 Psychiatric disorders incl. 61 deaths
  • 670    Renal and urinary disorders incl. 46 deaths
  • 352    Reproductive system and breast disorders incl. 1 death
  • 4,831 Respiratory, thoracic and mediastinal disorders incl. 365 deaths
  • 5,412 Skin and subcutaneous tissue disorders incl. 25  deaths
  • 427    Social circumstances incl. 12 deaths
  • 311    Surgical and medical procedures incl. 33 deaths
  • 2,850 Vascular disorders incl. 131 deaths

Total reactions for the experimental vaccine AZD1222/VAXZEVRIA (CHADOX1 NCOV-19) from Oxford/AstraZeneca: 2,848 deaths and 724,457 injuries

  • 8,125 Blood and lymphatic system disorders incl. 117  deaths
  • 10,935   Cardiac disorders incl. 351 deaths
  • 97       Congenital, familial and genetic disorders incl. 2 deaths
  • 7,746 Ear and labyrinth disorders
  • 263    Endocrine disorders incl. 2 deaths
  • 11,998   Eye disorders incl. 10 deaths
  • 75,897   Gastrointestinal disorders incl. 129 deaths
  • 195,671 General disorders and administration site conditions incl. 769 deaths
  • 450    Hepatobiliary disorders incl. 24 deaths
  • 2,765 Immune system disorders incl. 11 deaths
  • 15,657   Infections and infestations incl. 188 deaths
  • 6,783 Injury, poisoning and procedural complications incl. 57 deaths
  • 15,030   Investigations incl. 62 deaths
  • 9,083 Metabolism and nutrition disorders incl. 42 deaths
  • 113,983 Musculoskeletal and connective tissue disorders incl. 30 deaths
  • 275    Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl. 8 deaths
  • 155,571 Nervous system disorders incl. 438 deaths
  • 190    Pregnancy, puerperium and perinatal conditions incl. 3 deaths
  • 88       Product issues
  • 13,563   Psychiatric disorders incl. 25 deaths
  • 2,518 Renal and urinary disorders incl. 23 deaths
  • 4,578 Reproductive system and breast disorders
  • 23,942   Respiratory, thoracic and mediastinal disorders incl. 322 deaths
  • 33,090   Skin and subcutaneous tissue disorders incl. 18 deaths
  • 678    Social circumstances incl. 4 deaths
  • 571    Surgical and medical procedures incl. 16 deaths
  • 14,910   Vascular disorders incl. 197 deaths

Total reactions for the experimental COVID-19 vaccine JANSSEN (AD26.COV2.S) from Johnson & Johnson: 466 deaths and 25,950 injuries 

  • 240    Blood and lymphatic system disorders incl. 13 deaths
  • 392    Cardiac disorders incl. 48 deaths
  • 12       Congenital, familial and genetic disorders
  • 125    Ear and labyrinth disorders
  • 6         Endocrine disorders incl. 1 death
  • 305    Eye disorders incl. 3 deaths
  • 2,389 Gastrointestinal disorders incl. 18 deaths
  • 6,643 General disorders and administration site conditions incl. 120 deaths
  • 44       Hepatobiliary disorders incl. 3 deaths
  • 66       Immune system disorders
  • 322    Infections and infestations incl. 11 deaths
  • 267    Injury, poisoning and procedural complications incl. 7 deaths
  • 1,683 Investigations incl. 32 deaths
  • 140    Metabolism and nutrition disorders incl. 10 deaths
  • 4,429 Musculoskeletal and connective tissue disorders incl. 14 deaths
  • 14       Neoplasms benign, malignant and unspecified (incl cysts and polyps)
  • 5,457 Nervous system disorders incl. 57 deaths
  • 9         Pregnancy, puerperium and perinatal conditions incl. 1 death
  • 8         Product issues
  • 275    Psychiatric disorders incl. 3 deaths
  • 102    Renal and urinary disorders incl. 7 deaths
  • 85       Reproductive system and breast disorders
  • 907    Respiratory, thoracic and mediastinal disorders incl. 37 deaths
  • 556    Skin and subcutaneous tissue disorders incl. 1 death
  • 62       Social circumstances incl. 3 deaths
  • 293    Surgical and medical procedures incl. 23 deaths
  • 1,119 Vascular disorders incl. 54 deaths

These totals are based on EudraVigilance reports. Based on the percentage of reported adverse events, the totals could be significantly higher.

Some of these reports may also be sent to adverse reaction databases in individual countries, such as the VAERS database in the United States and the Yellow Card system in the United Kingdom.